LOS ANGELES and HONG KONG, May 18, 2011 /PRNewswire-Asia/ -- Artificial Life, Inc., (OTCBB: ALIFE), a leading provider of award-winning mobile technology and applications, announced today their upcoming product Opus-M™ Health: Neurodermatitis Kids Edition (short form: Opus-M Health: Nd Kids), a healthcare app specifically designed for children
Neurodermatitis is a serious skin disorder characterized by chronic itching and scratching. According to research and expert reports, it is particularly common among children*, with one child in ten of preschool age suffering from flaky and itchy areas of skin which characterize this condition.*
Artificial Life (ALIFE) has recently launched Opus-M Health: Neurodermatitis in the Apple App Store, an iOS healthcare application that serves as an electronic diary and monitoring tool for patients suffering from neurodermatitis. The upcoming of Opus-M Health: Neurodermatitis Kids Edition is an expansion of the original app and has been developed specifically for children affected by the skin disorder. The app encourages children to monitor and manage their skin conditions. The app contains unique features that are specially designed to be fun and easy to use by children, who will be able to use the app to help them keep track of neurodermatitis-related information (e.g. pain, itching, redness and weep) and as a result effectively monitor their conditions and healing processes over time.
Opus-M Health: Neurodermatitis Kids Edition features include:
As with all applications in the Opus-M Health family, the new version of the skin monitoring app will leverage Artificial Life's OPUS-M™ platform for end-consumers, healthcare providers, and healthcare businesses. The app is scheduled to launch in the Apple App Store in Q2 2011 and will be available later for Android and Windows Phone 7.
The Opus-M Health: Neurodermatitis Kids Edition follows the Company's successful launch of GluCoMo™, its diabetes monitoring app, and the standard version of Opus-M Health: Neurodermatitis. Artificial Life's Opus-M Health platform will continue to expand and feature more healthcare apps developed by the Company such as the upcoming application called Opus-M Health: HIV/AIDS that will be used for the management of HIV/AIDS. More information about the healthcare apps and mobile games by Artificial Life can be found at www.botme.com and www.artificial-life.com .
"We are happy to expand our Opus-M Health family with the upcoming launch of the Opus-M Health: Neurodermatitis Kids Edition. This new application reflects Artificial Life's efforts to develop a wide range of healthcare apps that will suit the needs of various age groups," said Eberhard Schoneburg, CEO of Artificial Life Inc.
1. Reitamo, S., Thomas A. Luger, and Martin Steinhoff. Textbook of Atopic Dermatitis. London: Informa Healthcare, 2008. Print.
2. "Effective treatment of children for neurodermatitis," HVBG, HVBG Web, April 28, 2011. <http://www.hvbg.de/e/pages/presse/preme/neurodermitis.html>.
About Artificial Life, Inc.
Artificial Life, Inc. has been a pioneer in artificial intelligence and mobile technology since its inception in Boston in 1994. We are a public US corporation (OTC BB: ALIFE) with listing on the Frankfurt Stock Exchange (Frankfurt: AIF.F; Xetra: AIF.DE) and headquarters and production center in Hong Kong. We have additional offices in Berlin, Germany (EMEA headquarters), Tokyo, Japan, and Santa Monica, USA. Currently our main business areas are: high quality (3D) interactive (massively multiplayer) mobile games, mobile participation television, mobile business applications, our powerful mobile commerce technology platform OPUS-M™ and our green IT solutions provided by Green Cortex, Inc. We have won many industry awards for our outstanding technology and products.
Facebook: http://www.botme.com/ref/alife-fb Twitter: http://twitter.com/alifegames MySpace: http://www.myspace.com/artificial_life_inc YouTube: http://www.youtube.com/user/alifegames
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding our future results of operations, financial condition and business prospects. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue" or the negative of these terms or other comparable terminology. Although such statements are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on them. These statements involve risks and uncertainties, and actual market trends or our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied in these forward looking statements for a variety of reasons. Potential risks and uncertainties include, but are not limited to, our ability to obtain additional funding to operate and grow our business; the unproven potential of our mobile gaming business model; changing consumer preferences and uncertainty of market acceptance of our products; timely adoption and availability of 3G mobile technology; market acceptance for use of mobile handheld devices to play the interactive games; unpredictable mobile game development schedules; our reliance on a relatively small number of brands; our ability to license brands from others; our dependence upon resellers and telecommunication carriers and operators to distribute our products; our ability to successfully develop, introduce, and sell new or enhanced products in a timely manner; and the timing of new product announcements or introductions by us or by our competitors. For additional discussion of these risks and uncertainties and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB filed on March 16, 2010. We assume no obligation to update any forward-looking statements, which apply only as of the date of this press release.
For more information on ARTIFICIAL LIFE, INC., please contact:Artificial Life IR and PR Contact: Adeline Law Tel: (+852) 3102 2800 email@example.com
SOURCE Artificial Life, Inc.
Subscribe to our Free Newsletters!
Nocturnal polyuria refers to increased urine output during night, without an associated increase in ...
Nootropics are drugs or substances which improve cognition that are being increasingly used ...
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...View All